Alpha Cognition vs X4 Pharmaceuticals
ACOG and XFOR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACOG and XFOR compare
X4 Pharmaceuticals is the larger company, worth 1.7 times as much as Alpha Cognition ($309M against $181M).
Alpha Cognition keeps more of each dollar of sales as profit, with a net margin of −145% compared with −813% at X4 Pharmaceuticals.
Alpha Cognition scores higher on the StockData Score (6 against 3 for X4 Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACOG | XFOR |
|---|---|---|
| Size and price | ||
| Market cap | $181M | $309M |
| Share price | $8.30 | $3.12 |
| Change, 1 year | 35.6% | −19.4% |
| Change, 5 years | −63.3% | −97.8% |
| Beta (5Y) | 0.34 | 1.41 |
| Employees | 72 | 45 |
| StockData Score | ||
| Total score | 6 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 0 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 8.9× (better) | 31.2× |
| P/B | 3.7× | 2.2× (better) |
| FCF yield | −17.1% | – |
| Fair value | $5.01 | – |
| Margin of safety | −65.7% | – |
| Growth | ||
| Revenue growth (TTM) | – | 73.7% |
| Revenue growth, 5Y average | – | 16.7% |
| Profitability | ||
| Gross margin | 92.9% (better) | 68.8% |
| Operating margin | −147% (better) | −812% |
| Net margin | −145% (better) | −813% |
| FCF margin | −153% | – |
| Return on equity | −72.9% (better) | −80.3% |
| Return on invested capital | −684% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −9.3× |
| Current ratio | 7.13 | 13.22 (better) |
| Altman Z-score | 4.50 (better) | −2.09 |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 48.7% | 103% |
| Held by insiders | 5.3% | 12.2% |
| Insider net buying, 12 months | $8.3M (better) | −$451K |
| Short interest, % of float | 2.0% | 9.2% |
Go deeper
- ACOG stock overview
- ACOG income statement
- ACOG valuation and score
- XFOR stock overview
- XFOR income statement
- XFOR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.